APD334

DRUG4 trials

Sponsors

Arena Pharmaceuticals, Arena Pharmaceuticals, Inc.

Conditions

Inflammatory Bowel DiseasesPrimary Biliary CholangitisPyoderma GangrenosumSkin Extra-intestinal Manifestationsautoimmune diseases

Phase 2

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

TerminatedNCT03072953

Arena PharmaceuticalsPyoderma Gangrenosum

Start: 2017-06-07End: 2018-05-22Updated: 2021-06-11

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

TerminatedNCT03139032

Arena PharmaceuticalsInflammatory Bowel Diseases, Skin Extra-intestinal Manifestations

Start: 2017-07-17End: 2017-12-06Updated: 2020-12-31

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

TerminatedNCT03155932

Arena PharmaceuticalsPrimary Biliary Cholangitis

Start: 2017-12-29End: 2019-01-31Updated: 2022-03-24

Unknown Phase

A randomized, double-blind, placebo and positive controlled, parallel group study to investigate the QTc exposure response, pharmacokinetics, safetyand tolerability after multiple therapeutic and supratherapeutic dosing of etrasimod (APD334) in healthy adult subjects

Active, not recruitingNL-OMON44472

Arena Pharmaceuticals, Inc.autoimmune diseases

Start: 2017-05-24Target: 60Updated: 2024-02-28